Beyond treatment volume: when pelvic radiotherapy may still matter in high-risk localised prostate cancer
Iván Henríquez, Oscar Abuchaibe, Barbara Malave-Chacon, Meritxell Arenas · 2026
Read Beyond treatment volume: when pelvic radiotherapy may still matter in high-risk localised prostate cancer by Iván Henríquez, Oscar Abuchaibe, Barbara Malave-Chacon, Meritxell Arenas (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13218880.txt.
Description
Whether to radiate the whole pelvis in high-risk prostate cancer has swung in and out of fashion for twenty years, and this 2026 article argues the debate is too simple. Ivan Henriquez and co-authors wrote the piece as treatment around the question has changed. Hormone therapy and stronger new hormone-blocking drugs now frame the choice.
Treating the pelvis aims at cancer cells hiding in nearby lymph nodes, but it raises side effects in bowel and bladder. The authors sort patients by biology, anatomy, and overall treatment plan rather than by habit. Their message is that volume alone is the wrong question. The right question is which patient, on which drug backbone, gains enough from pelvic treatment to justify its cost in side effects.
Catalog record
| CREATOR | Iván Henríquez, Oscar Abuchaibe, Barbara Malave-Chacon, Meritxell Arenas |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |